Transaction DateRecipientSharesTypePriceValue
9th February 2021Joseph C Galante4,000Open or private sale$74.03$296,120.00
26th August 2020Joseph C Galante225Open or private purchase$3.29$740.25
21st August 2020Joseph C Galante375Open or private purchase$3.35$1,256.25
14th August 2020Joseph C Galante375Open or private purchase$3.44$1,290.00
7th August 2020Joseph C Galante375Open or private purchase$3.42$1,282.50
31st July 2020Joseph C Galante375Open or private purchase$3.26$1,222.50
24th July 2020Joseph C Galante375Open or private purchase$3.33$1,248.75
17th July 2020Joseph C Galante375Open or private purchase$3.29$1,233.75
10th July 2020Joseph C Galante375Open or private purchase$3.31$1,241.25
2nd July 2020Joseph C Galante300Open or private purchase$3.34$1,002.00
Cumberland Pharmaceuticals
Cumberland Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.

Cumberland Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of prescription products. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Ticker: CPIX
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
SEC Central Index Key (CIK): 1087294
Employees: 80
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.
Red Flags
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
Fundamentals
Cash at Carrying Value: $27 M (-2%)
Inventory, Net: $8 M (0%)
Other Assets, Current: $2 M (-24%)
Assets, Current: $46 M (-8%)
Property, Plant and Equipment, Net: $632 Th (-15%)
Other Assets, Noncurrent: $3 M (-10%)
Assets: $98 M (-6%)
Accounts Payable, Current: $11 M (8%)
Liabilities, Current: $23 M (-6%)
Liabilities: $49 M (-8%)
Common Stock, Value, Issued: $49 M (-1%)
Common Stock, Shares, Issued: $15 M (0%)
Retained Earnings (Accumulated Deficit): $766 Th (-36%)
Stockholders' Equity (Parent): $48 M (-5%)
Liabilities and Equity: $98 M (-6%)
Revenue: $10 M (0%)
Cost of Revenue: $3 M (-38%)
Research and Development: $1 M (-54%)
Sales and Marketing: $4 M (-48%)
General and Administrative Expenses: $2 M (-48%)
Operating Income/Loss: $2 M (-53%)
Income before taxes: $2 M (-52%)
Provision for income taxes: $7 Th (-82%)
EPS (basic): $0.06 (-53%)
EPS (diluted): $0.06 (-53%)
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
News
Generic placeholder
Tracking John Rogers' Ariel Investments Portfolio - Q4 2020 Update

23rd February 2021

Generic placeholder
Tracking John Rogers' Ariel Investments Portfolio - Q3 2020 Update

20th December 2020